Policy UpdatesMedicaidJanuary 17, 2024

Clinical Criteria updates — September 2023

On September 21, 2023, and October 4, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits. 

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: Newly published criteria
  • Revised: Addition or removal of medical necessity requirements, new document number
  • Updates Marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Please note:

  • The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective date

Clinical Criteria number

Clinical Criteria title

New or revised

April 25, 2024

*CC-0248

Elrexfio (elranatamab-bcmm)

New

April 25, 2024

*CC-0249

Talvey (talquetamab-tgvs)

New

April 25, 2024

*CC-0250

Veopoz (pozelimab-bbfg)

New

April 25, 2024

*CC-0251

Ycanth (cantharidin)

New

April 25, 2024

*CC-0018

Pompe Disease

Revised

April 25, 2024

*CC-0021

Fabrazyme (agalsidase beta)

Revised

April 25, 2024

*CC-0046

Zinplava (bezlotoxumab)

Revised

April 25, 2024

CC-0182

Iron Agents

Revised

April 25, 2024

*CC-0068

Growth Hormones

Revised

April 25, 2024

CC-0156

Reblozyl (luspatercept)

Revised

April 25, 2024

*CC-0233

Rebyota (fecal microbiota, live – jslm)

Revised

April 25, 2024

*CC-0020

Natalizumab Agents (Tysabri, Tyruko)

Revised

April 25, 2024

CC-0064

Interleukin-1 Inhibitors

Revised

April 25, 2024

CC-0026

Testosterone Injectable

Revised

April 25, 2024

*CC-0247

Beyfortus (nirsevimab)

Revised

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

CABC-CD-048716-23-CPN48226

PUBLICATIONS: February 2024 Provider Newsletter